alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0001040956
<NAME> VERIO INC.
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                         506,055
<SECURITIES>                                   358,969
<RECEIVABLES>                                   41,336
<ALLOWANCES>                                     8,694
<INVENTORY>                                          0
<CURRENT-ASSETS>                               930,853
<PP&E>                                         269,132
<DEPRECIATION>                                  64,002
<TOTAL-ASSETS>                               1,763,724
<CURRENT-LIABILITIES>                          131,370
<BONDS>                                      1,071,073
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    347,304
<COMMON>                                       462,558
<OTHER-SE>                                   (276,739)
<TOTAL-LIABILITY-AND-EQUITY>                 1,763,724
<SALES>                                        258,336
<TOTAL-REVENUES>                               258,336
<CGS>                                           79,288
<TOTAL-COSTS>                                  376,403
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 9,572
<INTEREST-EXPENSE>                              87,183
<INCOME-PRETAX>                              (181,906)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (181,906)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (192,774)
<EPS-BASIC>                                     (2.56)
<EPS-DILUTED>                                   (2.56)


</TABLE>
[Federal Register Volume 60, Number 84 (Tuesday, May 2, 1995)]
[Notices]
[Page 21524]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10763]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made final findings of scientific misconduct in the following 
case:

    Catherine Coyle, ISOLAB, Inc. An investigation conducted by the 
ISOLAB found that Ms. Coyle, a former laboratory technician, falsified 
and misreported the results of assays for fetal hemoglobin data 
generated for Johns Hopkins' Multicenter Study of Hydroxyurea in Sickle 
Cell Anemia in biomedical research supported by Public Health Service 
funds under a cooperative agreement. Ms. Coyle admitted that she 
misrepresented data submitted to the Johns Hopkins clinical hydroxyurea 
study. There were no publications involved. Ms. Coyle executed a 
Voluntary Exclusion and Settlement Agreement in which she has agreed 
not to apply for Federal grant or contract funds and will not serve on 
PHS advisory committees, boards or peer review groups for a three-year 
period beginning March 27, 1995.

FOR FURTHER INFORMATION, CONTACT: Director, Division of Research 
Investigations Office of Research Integrity, 301-443-5330.
Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 95-10763 Filed 5-1-95; 8:45 am]
BILLING CODE 4160-17-P
EX-10.1







Exhibit 10.1




AMENDMENT TO AGREEMENT FOR SEVERANCE UPON CHANGE IN CONTROL




     This Amendment to Agreement For Severance Upon Change in Control (this “Amendment”) is entered
into as of the 16th day of December, 2008, by and between Transcat, Inc., an Ohio corporation (the
“Company”), having its principal place of business at 35 Vantage Point Drive, Rochester, New York
14624, and Charles P. Hadeed (the “Employee”).



     WHEREAS, the Company and the Employee entered into the Agreement For Severance Upon
Change in Control, effective February 12, 2004 (the “Agreement”); and



     WHEREAS, Section 8 of the Agreement provides that the Agreement may be amended by a written
amendment executed by the Company and the Employee; and



     WHEREAS, Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the
Treasury Regulations and other official guidance issued thereunder (collectively, “Section 409A”),
require that the Company’s compensation and benefit arrangements be in documentary compliance with
Section 409A on or before December 31, 2008, and this requires amendments to the Agreement as set
forth more fully below.



     NOW, THEREFORE, the Company and the Employee hereby agree as follows:


1. Section 2 is amended by adding a new subsection f. to read as follows:





“Termination” or “retirement” means a “separation from service” within the meaning
provided by Section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”), and the Treasury Regulations and other official guidance issued thereunder
(collectively, “Section 409A”).


2. Section 14 is added to the Agreement to read as follows:





SIX MONTH WAITING PERIOD. Notwithstanding anything to the contrary, to the
extent that any payments under this Agreement are subject to a six-month waiting
period under Section 409A, any such payments that would be payable before the
expiration of six months following the Employee’s separation from service but for
the operation of this sentence shall be made during the seventh month following the
Employee’s separation from service.


3. Section 15 is added to the Agreement to read as follows:





SECTION 409A. This Agreement and the compensation and benefits provided
hereunder are intended to be exempt from or to comply with the requirements of
Section 409A, and shall be interpreted and administered consistent with such intent.



     IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the
day and year first above written.



	 	 	 	 	 
	 	Transcat, Inc.

 	 
	 	By:  	/s/ Alan H. Resnick
 	 
	 
	 	Employee:

 	 
	 	/s/ Charles P. Hadeed
 	 
	 	Charles P. Hadeed
Johnquan JOHNSON, Appellant, v. STATE of Florida, Appellee.

No. 1D18-2518

District Court of Appeal of Florida, First District.

July 9, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
EXHIBIT A 

Case 5:17-cv-00603-EJD Document 26-1 Filed 03/13/17 Page 1 of 2
Case 5:17-cv-00603-EJD Document 26-1 Filed 03/13/17 Page 2 of 2
STIPULATION TO EXTEND DEADLINE TO COMPLETE JOINT SITE INSPECTION UNDER GENERAL 

ORDER 56 AND RELATED DATE; [PROPOSED] ORDER 

Page 1 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Tanya E. Moore, SBN 206683 

MISSION LAW FIRM, P.C. 

332 North Second Street 

San Jose, California 95112 

Telephone (408) 298-2000 

Facsimile (408) 298-6046 

E-mail: service@mission.legal 

Attorney for Plaintiff, 

Francisca Moralez 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

FRANCISCA MORALEZ, 

 Plaintiff, 

 vs. 

DARAKAR, INC., et al., 

 Defendants. 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

)

No. 4:17-cv-00648-KAW 

STIPULATION TO EXTEND DEADLINE 

TO COMPLETE JOINT SITE 

INSPECTION UNDER GENERAL 

ORDER 56 AND RELATED DATE; 

[PROPOSED] ORDER AS MODIFIED 

WHEREAS, on February 10, 2017, the Court issued a Scheduling Order for Cases 

Asserting Denial of Right of Access under the Americans with Disabilities Act (Dkt. 4) (“the 

Scheduling Order”); 

WHEREAS, Plaintiff Francisca Moralez (“Plaintiff”) and Defendants, Darakar, Inc., 

and Valero 1800 W 10th Street, Antioch, CA (“Defendants,” and together with Plaintiff, “the 

Parties”) have not yet had the opportunity to conduct the joint site inspection required pursuant 

to General Order 56 and the Scheduling Order; 

WHEREAS, Plaintiff filed a motion for substitution of counsel on July 5, 2018 (Dkt. 

28) that has been granted; 

NOW, THEREFORE, the Parties, by and through their respective counsel, stipulate to 

a continuance of the joint site inspection to a date on or after September 4, 2018, with all dates 
STIPULATION TO EXTEND DEADLINE TO COMPLETE JOINT SITE INSPECTION UNDER GENERAL 

ORDER 56 AND RELATED DATE; [PROPOSED] ORDER 

Page 2 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

triggered by that deadline continued accordingly; 

IT IS SO STIPULATED. 

Dated: July 6, 2018 MISSION LAW FIRM, A.P.C. 

 /s/ Tanya E. Moore 

 Tanya E. Moore 

 Attorney for Plaintiff, 

 Francisca Moralez 

Dated: July 6, 2018 VAUGHAN & ASSOCIATES 

 /s/ Cris C. Vaughan 

 Cris C. Vaughan 

 Attorneys for Defendants, 

Darakar, Inc., and Valero 1800 W 10th Street, 

Antioch, CA 

 

ATTESTATION 

Concurrence in the filing of this document has been obtained from each of the individual(s) 

whose electronic signature is attributed above. 

 /s/ Tanya E. Moore 

 Tanya E. Moore 

 Attorney for Plaintiff, 

 Francisca Moralez 

ORDER

 The Parties having so stipulated and good cause appearing, 

IT IS HEREBY ORDERED that the deadline for the Parties to complete the joint site 

inspection is extended to a date on or after September 4, 2018, with all dates triggered by that 

deadline continued accordingly 

IT IS SO ORDERED. 

Dated: 

 United States Magistrate Judge 

7/9/18
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

TERRY L. BAKER (SBN 214365)

820 Bay Avenue, Suite 230L

Capitola, CA 95010

Tel: (831) 476-7900

Fax: (831) 476-7906

tbaker@consumerlawgroup.net

Attorney for Plaintiff

ANTHONY J. BALESTERI III

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

SAN JOSE DIVISION

ANTHONY J. BALESTERI III, an

individual,

Plaintiff,

vs.

GRAND DESIGN RV, LLC, a limited

liability company,

Defendant.

Case 17-cv-00683-NC

STIPULATION FOR DISMISSAL OF

COMPLAINT WITH PREJUDICE AND

ORDER THEREON

It is hereby stipulated, by and between plaintiff and defendant, by and through their

respective counsel of record, that based on the settlement that the parties have entered into,

the above-captioned matter be dismissed, with prejudice, pursuant to FRCP 41(a)(1).

Dated: October 30, 2017 Respectfully submitted,

/s/ Terry L. Baker 

TERRY L. BAKER

Attorney for Plaintiff

///

///

///

///

Balesteri v. Grand Design RV, LLC. -1- STIPULATION FOR DISMISSAL
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Dated: October 30, 2017 Sutton & Murphy

/s/ Tom Murphy

TOM MURPHY

Attorney for Defendant

The parties having stipulated and good cause appearing therefor,

IT IS HEREBY ORDERED that the above-captioned matter is hereby dismissed with

prejudice.

Dated:

UNITED STATES DISTRICT JUDGE

Balesteri v. Grand Design RV, LLC. -2- STIPULATION FOR DISMISSAL
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     The schedule  contains  summary  financial  information  extracted from the
registrant's  financial  statements  as of and for the nine month  period  ended
December  27,  1997,  and is  qualified  in its  entirety by  reference  to such
financial statements:
</LEGEND>

       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                              Mar-28-1998 
<PERIOD-END>                                   Dec-27-1997 
<CASH>                                           2,159,746 
<SECURITIES>                                             0 
<RECEIVABLES>                                            0 
<ALLOWANCES>                                             0 
<INVENTORY>                                      2,762,829 
<CURRENT-ASSETS>                                 5,183,381 
<PP&E>                                           3,959,110 
<DEPRECIATION>                                   2,655,094 
<TOTAL-ASSETS>                                   6,638,698 
<CURRENT-LIABILITIES>                            4,269,040 
<BONDS>                                                  0 
<PREFERRED-MANDATORY>                                    0 
<PREFERRED>                                        500,000 
<COMMON>                                           548,892 
<OTHER-SE>                                        (104,559)
<TOTAL-LIABILITY-AND-EQUITY>                     6,638,698 
<SALES>                                         13,049,605 
<TOTAL-REVENUES>                                13,049,605 
<CGS>                                            8,057,685 
<TOTAL-COSTS>                                    8,057,685 
<OTHER-EXPENSES>                                 5,085,151 
<LOSS-PROVISION>                                         0 
<INTEREST-EXPENSE>                                 175,217 
<INCOME-PRETAX>                                   (299,299)
<INCOME-TAX>                                             0 
<INCOME-CONTINUING>                               (299,299)
<DISCONTINUED>                                           0 
<EXTRAORDINARY>                                          0 
<CHANGES>                                                0 
<NET-INCOME>                                      (299,299)
<EPS-PRIMARY>                                        (.01) 
<EPS-DILUTED>                                        (.01) 
                                               


</TABLE>
Devin J. CHAMPANGE, Appellant, v. STATE of Florida, Appellee.

Case No. 5D18-3771

District Court of Appeal of Florida, Fifth District.

Decision filed July 2, 2019

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
[Federal Register Volume 60, Number 84 (Tuesday, May 2, 1995)]
[Notices]
[Page 21513]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10683]



-----------------------------------------------------------------------


DEPARTMENT OF ENERGY
[Docket No. RP95-244-000]


Williams Natural Gas Co.; Notice of Proposed Changes in FERC Gas 
Tariff

April 26, 1995.
    Take notice that on April 21, 1995, Williams Natural Gas Company 
(WNG) tendered for filing to become part of its FERC Gas Tariff, Second 
Revised Volume No. 1, Second Revised Sheet No. 240. The proposed 
effective date of these tariff sheets is May 4, 1995.
    WNG states that the purpose for the instant filing is to comply 
with the Commission's order in Docket No. RM95-5 issued March 29, 1995. 
Second Revised Sheet No. 240 includes revisions to Article 11 of WNG's 
FERC Gas Tariff to provide that releases for a period of one month or 
less will be considered short term releases, and releases for more than 
one month are long term releases. It also provides that long term pre-
arranged releases at the maximum rate will be exempted from the advance 
posting and bidding requirements.
    WNG states that a copy of its filing was served on all 
jurisdictional customers and interested state commissions.
    Any person desiring to be heard or to protest said filing should 
file a motion to intervene or a protest with the Federal Energy 
Regulatory Commission, 825 North Capitol Street, N.E., Washington, D.C. 
20426, in accordance with Sections 385.214 and 385.211 of the 
Commission's Rules and Regulations. All such motions or protests should 
be filed on or before May 3, 1995. Protests will be considered by the 
Commission in determining the appropriate action to be taken, but will 
not serve to make protestants parties to the proceeding. Any person 
wishing to become a party must file a motion to intervene. Copies of 
this filing are on file with the Commission and are available for 
public inspection in the Public Reference Room.
Lois D. Cashell,
Secretary.
[FR Doc. 95-10683 Filed 5-1-95; 8:45 am]
BILLING CODE 6717-01-M
[Federal Register Volume 60, Number 2 (Wednesday, January 4, 1995)]
[Notices]
[Page 443]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-81]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Defense Intelligence Agency, Scientific Advisory Board Panel 
Closed Meeting

AGENCY: Department of Defense, Defense Intelligence Agency.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Pursuant to the provisions of Subsection (d) of Section 10 of 
Public Law 92-463, as amended by Section 5 of Public Law 94-409, notice 
is hereby given that a closed meeting of the DIA Scientific Advisory 
Board has been scheduled as follows:

DATES: January 10, 1995 (830 to 400).

ADDRESSES: The Defense Intelligence Agency, Pentagon, Washington, D.C. 
20340.

DATES: January 11, 1995 (830 to 400).

ADDRESSES: The Defense Intelligence Agency, Bolling AFB, Washington, 
D.C. 20340-5100.

FOR FURTHER INFORMATION CONTACT: Dr. W.S. Williamson, Executive 
Secretary, DIA Scientific Advisory Board, Washington, D.C. 20340-1328 
(202) 373-4930.

SUPPLEMENTARY INFORMATION: The entire meeting is devoted to the 
discussion of classified information as defined in Section 552b(c)(I), 
Title 5 of the U.S. Code and therefore will be closed to the public. 
The Board will receive briefing on and discuss several current critical 
intelligence issues and advise the Director, DIA, on related scientific 
and technical matters.

    Dated: December 28, 1994.
L.M. Bynum,
Alternate OSD Federal Register, Liaison Officer, Department of Defense.
[FR Doc. 94-81 Filed 1-3-94; 8:45 am]
BILLING CODE 5000-04-M
Marcus JACKSON, Appellant, v. STATE of Florida, Appellee.

No. 1D18-2477

District Court of Appeal of Florida, First District.

June 17, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

KENRICH ATHLETIC CLUB,

 Petitioner

 v.

19TH & SANSOM CORP.,

 Respondent

:

:

:

:

:

:

:

:

:

:

:

No. 486 EAL 2014

Petition for Allowance of Appeal from the

Order of the Commonwealth Court

ORDER

PER CURIAM

AND NOW, this 10th day of March, 2015, the Petition for Allowance of Appeal is

DENIED.
[Federal Register Volume 60, Number 79 (Tuesday, April 25, 1995)]
[Notices]
[Page 20259]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10079]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability of Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patents Concerning Anticonvulsant and Neuroprotective 
Agents

AGENCY: U.S. Army Medical Research and Materiel Command, Department of 
the Army, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent No. 5,258,386 entitled ``(+)-
3-Substituted-N-Alkylmorphinans, Synthesis and use as Anticonvulsant 
and Neuroprotective Agents'' and issued on November 1, 1993, and U.S. 
Patent No. 5,331,010 entitled ``1-Phenylalkanecarboxylic Acid 
Derivatives as Anticonvulsant and Neuroprotective Agents; and issued on 
July 19, 1994. These patents have been assigned to the United States 
Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.

FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, (301) 619-2065 or telefax (301) 
619-7714.

SUPPLEMENTARY INFORMATION: The inventions represent discoveries that 
members of certain classes of compounds [(+)-3-substituted-N-
alkylmorphinans and 1-phenylalkanecarboxylic acids] possess effective 
usefulness as nonaddictive anticonvulsant and neuroprotective agents. 
The 1-phenylalkanecarboxylic acids include novel non-opiate derivatives 
as well as previously published species. Methods for controlling 
convulsions in a variety of pharmaceutical formulations and modalities 
are described. In both inventions, novel compounds which possess these 
biological properties are presented in a method or methods of use for 
preventing, treating, or controlling convulsions in mammals having a 
need for such treatment. The compounds do not lead to dependency, have 
low toxicity, and provide effective anticonvulsant or neuroprotective 
treatment with little or no behavioral detriment to the recipient.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 95-10079 Filed 4-24-95; 8:45 am]
BILLING CODE 3710-08-M
UNIVERSAL PROPERTY & CASUALTY INSURANCE COMPANY, Appellant/Petitioner(s), v. Deborah PEARCE and Joseph Pearce, Appellee/Respondent(s).

CASE NO.: 2D19-2738

District Court of Appeal of Florida, Second District.

August 15, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Appeal is dismissed.
Exhibit 32.1




                                    CERTIFICATION PURSUANT TO
                                         18 U.S.C. SECTION 1350,
                                      AS ADOPTED PURSUANT TO
                       SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Noble Roman's, Inc. (the "Company")
on Form 10-Q for the period ended March 31, 2008 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Paul W. Mobley,
Chief Executive Officer and Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section  1350, as adopted pursuant to Section  906 of the
Sarbanes-Oxley Act of 2002, that:

     (1) The Report fully complies with the requirements of section 13(a) or
         15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
         material respects, the financial condition and results of operations of
         the Company.


                             /s/ Paul W. Mobley
                             ---------------------------------------------------
                             Paul W. Mobley
                             Chief Executive Officer and Chief Financial Officer
                             of Noble Roman's, Inc.

                             Date:




                                                      19